Performance and safety of the Colovac 2 colorectal anastomotic protection device: the SafeHeal SAFE-2023 study - Top-Institutions - MDSpire

Performance and safety of the Colovac 2 colorectal anastomotic protection device: the SafeHeal SAFE-2023 study

  • By

  • Lefevre, Jeremie H.

  • Karachun, Aleksei

  • Sametdinov, Narkhodzha

  • Raximov, Oqiljon

  • Rustamov, Akmalkhuja

  • Adilkhodjaev, Askar

  • Yunusov, Seydamet

  • Mirzagolib, Tillyashaikhov

  • Sylla, Patricia

  • March 5, 2026

  • 0 min

Share

Top Institutions in Surgery

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Colorectal Surgery
    • Gastrointestinal Surgery
    • Surgical Innovation

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Colorectal Surgery
    • Surgical Oncology
    • Gastrointestinal Research

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Colorectal Surgery
    • Oncologic Surgery
    • Clinical Trials

  • #4

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Colorectal Surgery
    • Gastrointestinal Surgery
    • Surgical Innovation

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Colorectal Surgery
    • Gastrointestinal Surgery
    • Clinical Research

Original Source(s)

Performance and safety of the Colovac 2 colorectal anastomotic protection device: the SafeHeal SAFE-2023 study

  • by Lefevre, Jeremie H., Karachun, Aleksei, Sametdinov, Narkhodzha, Raximov, Oqiljon, Rustamov, Akmalkhuja, Adilkhodjaev, Askar, Yunusov, Seydamet, Mirzagolib, Tillyashaikhov, Sylla, Patricia

  • March 5, 2026

Related Content

7 Days Noninferior in Bacteremia

BALANCE compared 7 vs 14 days of treatment among hospitalized patients with bloodstream infections.

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.

Postoperative Step Counts Tied to Surgical Recovery

Wearable-measured mobility—but not heart rate variability or wellness scores—was associated with length of stay, complications, and readmissions